Dr. Danae Delivanis on Pembrolizumab and Nivolumab in Metastatic Melanoma
Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.
Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma. Delivanis says while the two treatments have improved the overall survival of patients with metastatic melanoma by 7 months, clinicians should be aware of the thyroiditis and hypothyroidism that can occur as a side effect of the treatments.
In a retrospective study conducted by Delvanis in 94 patients on both treatments,she says there were no differences in occurrence between male and female patients. The median age of participants in the study was 58 years old and the onset of the side effects were about 6 weeks since the tart of treatment.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
